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We determined mutations in the BRAF, N-ras, and CDKN2A genes in 27 histologically diverse melanocytic nevi and
corresponding surrounding tissues from 17 individuals. Mutations in the BRAF and N-ras gene were found in 22
nevi (81%) from 16 individuals (94%). The predominant BRAF mutation T1799A (V600E) was detected in 18 nevi; 1
nevus had a novel A1781G (D594V) mutation in the same gene and 3 nevi had mutations in codon 61 of the N-ras
gene. In 4 individuals both nevi carried a BRAF mutation, whereas in 2 other individuals 1 nevus showed a BRAF
mutation and the second nevus had an N-ras mutation. In 2 individuals normal skin distant from nevi showed a
BRAF mutation. No mutations were detected in the CDKN2A gene. The mutations in the BRAF and N-ras genes, in
this study, were not associated with histologic type, location, skin type, size, or numbers of nevi. Our results
suggest that mutations in the BRAF gene and to some extent in the N-ras gene represent early somatic events that
occur in melanocytic nevi. We hypothesize the dual effect of solar ultraviolet irradiation on melanoma, through
mutagenesis and by increasing the number of melanocytic nevi, many of which carry a BRAF or N-ras mutation.
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Cutaneous malignant melanoma (CMM) is a potentially fatal
neoplasm with complex and heterogeneous etiology (Chin
et al, 1998). Epidemiologic data, besides supporting a role
of sunlight exposure, associate a high number of acquired
benign melanocytic nevi with the increased melanoma risk
(Gilchrest et al, 1999; Naldi et al, 2000; Hemminki et al,
2001). Melanocytic lesions are classified as junctional with
lesion present at the epidermal–dermal interface, intrader-
mal with melanocytic cells present in the dermis, and
compound where lesion is present at both the interface and
the dermis (Dore et al, 2001). The incidence of melanoma
appears to be higher in the populations who develop nevi
early in life, and evidently increased sun exposure is related
to the number of nevi (Harrison et al, 2000). These data
suggest that the number of nevi may be marker of sun
exposure. Accordingly, results from twin studies suggested
that in adolescents environmental exposure affects the
mean number of nevi; however, the emergence of nevi is
genetically controlled (Bataille et al, 2000; Wachsmuth et al,
2001). A recent epidemiologic study has proposed diver-
gent pathways to melanoma, one associated with melano-
cyte proliferation after initiation by sunlight and another with
chronic exposure to sunlight (Whiteman et al, 2‘003). The
genetic events that translate the effect of solar exposure
into the risk of melanoma have not been clearly understood
as ‘‘fingerprint’’ mutations like those in the p53 gene in
nonmelanoma skin cancers are rare in melanoma (Kumar
et al, 2001).
The germline mutations in the CDKN2A gene are the
most important known genetic risk factors in familial
melanoma, yet the genetic and epigenetic alterations at
the CDKN2A locus genes in sporadic melanoma are rare
and rather absent in melanocytic nevi (Kumar et al, 1999;
Welch et al, 2001; Bishop et al, 2002; Hayward, 2003). A
study based on genomewide mutations detection strategy
has revealed activating alterations in the BRAF gene in a
number of cancers, particularly in a high proportion of
melanomas (Davies et al, 2002). Significantly, in a recent
study activating mutations in the BRAF gene were also
identified in melanocytic nevi, which suggested that these
alterations constituted a crucial step in melanoma initiation
(Pollock et al, 2003). Nevertheless, these mutations per se
are evidently not sufficient for transformation of melano-
cytes into cutaneous melanoma. Although melanocytic nevi
are suggested to be clinically and histologically associated
with melanoma, their role as premalignant lesions of
melanoma is unclear, in part owing to heterogeneity of nevi
and inadequate understanding of accompanying genetic
alterations and their potential to transformation (Pollock
et al, 2003). Although roughly only half or less of the
melanomas are histologically associated with nevi, the risk
per surface area is much larger in nevi than in surrounding
skin where fewer melanocytes reside (Skender-Kalnenas
et al, 1995).
The relevance of mutations in the BRAF and N-ras genes
in melanomas and melanocytic nevi is due to growing
evidence that oncogenic activation of the Ras/Raf/MEK/
ERK pathway may be involved in melanoma (Smalley,
2003). The importance of BRAF in melanoma biology has
been confirmed by the role of these mutations in constitu-
tive activation of ERK in melanoma cell lines (Satyamoorthy
et al, 2003). The mutual exclusivity between mutations in the
Abbreviations: BCC, basal cell carcinoma; CMM, cutaneous
malignant melanoma; SSCP, single-strand conformation poly-
morphism.
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BRAF and different Ras genes in various tumors, including
melanoma and melanocytic nevi, points to the linear
functional relationship for these components in the complex
signaling pathways (Brose et al, 2002; Rajagopalan et al,
2002; Yuen et al, 2002; Pollock et al, 2003).
To further understand the nature and relevance of the
activating alterations in the BRAF and N-ras genes, we have
screened 27 melanocytic lesions and corresponding sur-
rounding tissues from 17 individuals. We also screened nevi
and surrounding tissues for mutations in the CDKN2A gene.
Furthermore, we have attempted to hypothesize the links
between these mutations in nevi and their possible
mediatory role in translating sun exposure to the risk of
melanoma.
Results
Mutations in the BRAF, N-ras, and the CDKN2A genes in
melanocytic nevi and surrounding tissues Twenty-seven
melanocytic nevi and corresponding surrounding and
control tissues from 17 individuals were analyzed for
mutations in exons 11 and 15 of the BRAF gene, exons 1
and 2 of the N-ras gene, and exons 1 to 3 of the CDKN2A
gene using PCR-SSCP/heteroduplex and sequencing (Fig
1). Mutations in either BRAF or N-ras genes were detected
in 22 of 27 (81%) nevi analyzed in this study. Thus, 16 of the
17 (94%) individuals involved in the study carried mutations
in the benign moles. Mutations in the BRAF gene were
predominant, being present in 19 nevi, compared to
mutations in the N-ras gene that were detected in 3 nevi.
The ‘‘hot spot’’ codon 600 (previously 599) alteration
T1799A (previously 1796) in exon 15 of the BRAF gene
was present in 18 nevi (Fig 1B,D); 1 nevus carried a
previously unreported A1781G (D594V) mutation in the
conserved domain of the BRAF gene (Table I; Fig 1A,C). The
A1781G mutation in exon 15 of the BRAF gene was
detected only as a double-stranded heteroduplex (Fig 1A).
(In all communications on mutations in the BRAF gene, the
nucleotide and codon numbers have been based on the
NCBI gene bank nucleotide sequence NM_004333. Accord-
ing to sequence given in NCBI gene bank sequence
accession number NT_007914, however, there is a dis-
crepancy of one codon (three nucleotides) in exon 1 in the
sequence NM_004333. The sequence analysis of exon 1 of
the BRAF gene in our laboratory has shown that the
sequence derived from NT_007914 is correct (Kumar et al,
Clin Cancer Res 9:3362–3368, 2003). Because of the
correctness of the latter, sequence numbering of codons
and nucleotides after exon 1 is changed by þ 1 and þ3,
respectively.) No mutation was detected in exon 11 of the
BRAF gene. Three nevi carried mutations in codon 61 of the
N-ras gene, whereas no mutation was present in codons 12
and 13. Mutations in the BRAF and N-ras were mutually
Figure 1
Detection of BRAFmutations in melanocytic nevi (B) An autoradiograph showing SSCP analysis for the detection of T1799A (V600E) mutation in
exon 15 of the BRAF gene. Aberrant band shifts in lanes 2, 4, and 6 are due to the mutations in DNA from nevi from cases 16 and 17. Lane 1,
migration pattern of wild-type single strands of amplified DNA from the surrounding tissue corresponding to one nevus from case 16; lane 2,
aberrant band owing to mutation in second nevus from case 16; lane 3, amplified DNA from corresponding surrounding tissue; lane 4, DNA from one
nevus from case 17 with mutation; lane 5, corresponding surrounding tissue; lane 6, DNA from second nevus from case 17; lane 7, DNA from
corresponding surrounding tissues; lanes 8 and 9, no template controls; and lane 10, a control DNA. (A) An autoradiograph showing heteroduplex
analysis of exon 15 fragment of the BRAF gene in nevi and corresponding surrounding tissues. The double-strand DNA in lane 6 shows the aberrant
band shift owing to A1781G (D594V) mutation in the BRAF gene in one nevus from case 8. This mutation did not cause any shift in the single strands.
Lane 7, DNA from corresponding surrounding tissue. (D) Sequence analysis showing T1799A mutation (arrow) in exon 15 of the BRAF gene in nevus
from case 16. (C) Part of sequence showing A1781G mutation (arrow) in exon 15 of the BRAF gene in nevus from case 8. (E) Part of sequence of
exon 15 of the BRAF gene obtained from a control DNA (from lymphocytes of a healthy individual) corresponding to wild-type sequence reported in
gene data bank (accession No. NT_007914). Arrows, the positions of mutations in nevi from cases 8 and 16.
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Table I. Types of melanocytic nevi and surrounding tissues screened
and mutations detected in the BRAF and N-ras genes
Case Status Tissue Clinical type Size (mm2) Color Site Skin typea No. of moles BRAF N-ras
1 Nevus Intradermal 54 Red-brown Breast II 6–10 T4Ab —
Surroundingc — —
2 BCC Nevus Compound 42 Red-brown Breast III 1–5 T4A —
Surrounding — —
3 Nevus Compound 91 Red-brown Abdomen II 4100 T4A —
Surrounding — —
4 Nevus Compound 35 Brown Arm II 4100 — C4Ad
Surrounding — —
5 Nevus Junctional 24 Brown Buttocks I 50–100 T4A —
Surrounding — —
6 Nevus Intradermal 28 Brown Side I 6–10 T4A —
Surrounding — —
7 CMM Nevus Junctional 20 Dark-brown Back I 21–50 — —
Surrounding — —
8 CMM/BCC Nevus Compound 63 Brown Back II 4100 A4Ge —
Surrounding — —
Nevus Junctional 36 Brown Back — —
Surrounding — —
9 Nevus Junctional 30 Brown Side III 50–100 T4A —
Surrounding T4A —
Nevus Intradermal 25 Brown Side — —
Surrounding — —
10 Nevus Compound 96 Dark-brown Back I 50–100 T4A —
Surrounding — —
Nevus Junctional 35 Brown Back — C4A
Surrounding — —
11 CMM Nevus Compound 12 Dark-brown Back II 50–100 — —
Surrounding — —
Nevus Compound 12 Brown Back T4A —
Surrounding — —
12 Nevus Intradermal 16 Light-brown Buttocks I 21–50 T4A –
Surrounding — —
Nevus Junctional 28 Dark-brown Leg — A4Gf
Surrounding — —
13 CMM Nevus Intradermal 16 Light-brown Shoulder II 50–100 T4A —
Surrounding T4A —
Nevus Intradermal 20 Light-brown Upper-arm T4A —
Surrounding — —
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exclusive as none of the nevus carried alterations con-
comitantly in both genes (Table I). In this study in two cases
we detected mutations similar to nevi in the corresponding
surrounding tissues. The melanocytic nevi and surrounding
tissues were from a maximal distance from each other;
however, the presence of trailing nevus cells in the adjacent
skin cannot be entirely ruled out. We did not find any
mutation in the skin samples taken from buttocks of all
the individuals included in the study. No mutations were
detected in the CDKN2A gene in any of the nevi or
surrounding tissues.
Mutations in the BRAF and N-ras genes were found in
both nevi in 6 of 10 individuals from whom two nevi each
were excised and screened (Table II). These included 2
cases were one nevus carried mutation in the BRAF gene
and the second nevus had mutation in the N-ras gene. In 4
individuals both nevi carried a V600E (previously V599E)
mutation in the BRAF gene; in another 4 individuals only one
of the two nevi screened carried a mutation. The frequency
of mutations in the BRAF and N-ras genes was lower in nevi
from melanoma patients (0.67) than the nevi from healthy
individuals (0.93) but the difference was not statistically
significant (Fisher’s exact test, p  0.13) (Table II). Similarly
a statistically nonsignificant difference (Fisher’s exact test,
p  0.32) in mutation frequency was also observed be-
tween large (surface area 30–96 mm2; 0.92) and small
(surface area 12–28 mm2; 0.72) nevi (Table II). No significant
difference was observed in mutation frequency among nevi
with different histologic types, compound (0.81), intradermal
(0.90), and junctional (0.66). No association was observed
between the nevi location and frequency of mutations in
BRAF and N-ras genes; likewise, skin phototype had no
effect on the frequency of mutations in nevi (Table II).
Discussion
Our results on mutation screening of 27 histologically
diverse melanocytic nevi and corresponding surrounding
tissues from a group of 17 individuals, composed of healthy
individuals, melanoma patients, and one basal cell carci-
noma (BCC) of the skin patient, confirm the presence of
somatic alterations in the BRAF and N-ras genes at a very
high frequency, indicating that these mutations are early
events in pathway to melanoma development. In conforma-
tion with earlier studies on melanoma and melanocytic nevi,
the mutations in the BRAF gene were overwhelmingly more
than in the N-ras gene, and also mutations in two genes
were mutually exclusive. With a single exception all the nevi
with BRAF mutation carried T1799A transition at hot spot
codon 600 (previously 599) where substitution probably
leads to conformational changes that mimic activational
phosphorylation at the adjacent residues (Zhang and Guan,
2000; Davies et al, 2002; Pollock and Meltzer, 2002). The
residue at codon 600 (previously 599) is identical at
corresponding positions in RAF1 and ARAF1 and is
Case Status Tissue Clinical type Size (mm2) Color Site Skin typea No. of moles BRAF N-ras
14 CMM Nevus Intradermal 30 Red-brown Shoulder II 4100 T4A —
Surrounding — —
Nevus Compound 40 Light-brown Shoulder T4A —
Surrounding — —
15 Nevus Compound 20 Dark-brown Neck III 1–5 T4A —
Surrounding — —
Nevus Compound 12 Brown Thigh T4A —
Surrounding — —
16 CMM Nevus Compound 20 Dark-brown Back II 50–100 — —
Surrounding — —
Nevus Intradermal 56 Reddish Upper-arm T4A —
Surrounding — —
17 Nevus Intradermal 45 Red-brown Back III 21–50 T4A —
Surrounding — —
Nevus Intradermal 24 Red-brown Back T4A —
Surrounding — —
aFitzpatrick skin phototypes.
bT1799A (V600E) mutation in the BRAF gene.
cNonnevus tissue taken from boat-shaped excision containing nevus (see Materials and Methods for details).
dCAA4AAA mutation in codon 61 of the N-ras gene.
eA1781G (D594V) mutation in the BRAF gene.
fCAA4CGA mutation in codon 61 of the N-ras gene.
Table I. Continued
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conserved through evolution with a single exception of the
Drosophila Raf homolog (Davies et al, 2002; Yuen et al,
2002). The mutant V600E (previously V599E) has been
reported to possess a 10-fold increased basal activity, and it
induces focus formation in NIH3T3 cells with much higher
efficiency than wild-type BRAF (Davies et al, 2002). The only
other mutation in the BRAF gene in melanocytic nevi was a
novel alteration A1781G in the activation segment, resulting
in aspartic acid to valine substitution at another evolutio-
narily conserved residue 594. Mutations in the N-ras gene
detected in three nevi involved codon 61, which have been
reported previously from melanomas localized at the skin-
exposed sites (Jiveskog et al, 1998). Our data on mutations
in normal skin distant from nevus suggest the possibility
that even melanocytes spread outside nevi can carry BRAF
mutation, and the genetic mechanism in these melanocytes
may not be different from those within the moles.
The acquired melanocytic nevi, which are a focal
collection of nondendritic melanocytes, are formed after
birth either spontaneously or in response to various factors
like exposure to sun. Since nevi have been suggested to
be senescent clones of melanocytes; thereby, these are
considered potential premalignant lesions (Robinson et al,
1998; Bennett, 2003). Our results that two individuals
carried different mutations in two nevi suggest that
mutations in the BRAF and N-ras genes arise in melano-
cytic nevi as consequences of independent somatic events,
which if followed by further, hitherto unknown genetic
events can lead to melanoma development. Because no
significant difference in mutation frequency in these genes
was observed in melanocytic nevi based on size, histologic
or skin type, or disease status, it is possible that alterations
in the genes involved in cAMP-dependent signaling path-
ways are acquired and selected owing to some growth
advantage in the early cellular phase.
The data from animal models and cell biology experi-
ments have increasingly indicated the role of extracellular
signaling pathways in melanoma biology and the interaction
of these pathways with downstream cell cycle regulators
(Noonan et al, 2001; Walker and Hayward, 2002). RAF
serine/threonine kinases are the key signaling components
in the RAS pathway (Kolch, 2000; Smalley, 2003). An
activated RAS interacts and stimulates a multitude of
downstream signaling cascades (Shields et al, 2000). In
melanocytes, BRAF, one of the members of the RAF family,
is activated in a cAMP-dependent signaling cascade as a
consequence of a-melanocyte-stimulating-hormone and
related peptides binding to MC1R, a G-protein-coupled
receptor (Busca et al, 2000; Halaban, 2000). Increased
cAMP is also involved in activation of tyrosinase, which
depending on its activity leads to the synthesis of
pheomelanin or eumelanin (Suzuki et al, 1999; Sturm,
2002). The eumelanogenesis, which is central to tanning,
has a protective effect on skin, whereas pheomelanin
generates free radicals under the influence of ultraviolet
light (Rees, 2000; Schaffer and Bolognia, 2001). Despite the
relationship between the numbers of melanocytic nevi and
risk of melanoma, and between sun exposure and timing of
acquisition of nevi, from the mutational data it is difficult to
infer the influence of sunlight on occurrence of mutations
in BRAF and N-ras genes. Nevertheless, acquisition of
mutations through pheomelanin-generated free radicals
and their selection in critical genes remains a possible
mechanism. We speculate that the role of sunlight may have
a dual effect on melanogenesis, one in causing mutations
and a second in increasing the number of melanocytic nevi.
The underlying genetic alterations in development of
melanoma from precursor lesions have remained something
of an enigma. Moreover, not all melanocytic nevi are
transformed into cutaneous melanoma. A recent survey
has estimated that for a 20-year-old individual, the lifetime
risk of any selected mole transforming into melanoma by
age 80 is approximately 0.03% and the annual transforma-
tion rate of any mole is 5  104 or less that increases to
3  103 for men older than 40 years (Tsao et al, 2003).
These estimates clearly suggest involvement of multiple
genetic hits in the transformation of a mole through
melanoma, which is in conformation with epidemiologic
results that associate increased risk with increased number
of nevi as that would increase the chance of mutation
accumulation.
The discovery of mutations at a high frequency in the
BRAF gene in melanomas and melanocytic nevi represents
an important step in understanding of melanoma genetics.
The majority of melanoma, but not all, carry mutations in the
BRAF and N-ras genes and not all melanoma arise from
nevi. Therefore, it is reasonable to assume that mutations
in these genes are early but not sufficient events for
melanoma initiation and progression. Nevertheless, our
data on inverse relationship between mutations in the
BRAF and N-ras genes and allelic loss on chromosome 9
did suggest the important and an overriding effect of such
mutations (Kumar et al, 2003b). Thus, from our results in this
study, we conclude that mutations in BRAF and N-ras in
melanocytic nevi constitute early key somatic events and
further genetic alterations are most likely required for
transformation into melanoma.
Materials and Methods
The study included 17 individuals (with Fitzpatrick skin phototypes I–III)
recruited, after institutional approval, for measurement of DNA repair
kinetics in vivo in benign melanocytic nevi and corresponding
surrounding normal tissues in Pa¨ija¨t-Ha¨me Central Hospital, Lahti,
Finland (Zhao et al, 2002a, b). The sampling was carried out in
accordance with the Helsinki Declaration. Five of the individuals were
CMM patients, 1 had both CMM and BCC, 1 was a BCC patient, and
the others were healthy individuals (Table I). The mean age of the CMM
group was 51.7  12.9 years and for healthy individuals 43.0  17.0
years. The nevus tissue was taken by punch biopsy from the middle of
moles. The rest, including residual nevus and nonnevus tissues, were
excised in boat-shape cuts. The normal tissue was cut from the distant
edge of the boat-shaped excision to exclude nevus tissue. The moles
were assessed for color, border, and symmetry and only symmetrical,
benign-looking moles with no recent change in outlook were removed
for the study. The clinical type of the mole (junctional, compound, or
intradermal) and their color were defined before biopsy (Table I). All the
biopsies were stored at 201C until DNA extraction. DNA was isolated
from 27 nevi, corresponding surround tissues (1 nevus each from 7
individuals and 2 nevi from other 10 individuals), and 17 buttock skin
biopsies (1 from each individual) as described earlier (Zhao et al,
2002a, b).
PCR and single-strand conformation polymorphism (SSCP)/
heteroduplex analysis. Exons 11 and 15 of the BRAF gene, exons 1
and 2 of the N-ras gene, and exons 1 to 3 of the CDKN2A gene were
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amplified for combined SSCP/heteroduplex analysis in all DNA
samples (from nevi and corresponding adjacent skin tissues) using
primers described in Exon III and earlier (Kumar et al, 1998, 2003a).
Briefly, PCR was carried in a 10-mL volume containing 50 mM KCl,
0.11 mM of each dNTP, 1 mCi of [a-32P]dCTP, 0.3 U of Taq DNA
polymerase, 1 to 2 mM MgCl2, and 0.15 to 0.3 mM of each primer. The
temperature for PCR was set as denaturation at 951C for 1 min,
annealing (at temperatures specific for each exon as given in Table II)
for 1 min, and polymerization at 721C for 1 min for 3 cycles followed by
27 to 33 cycles at same temperatures with the segment time of 30 s
each. The electrophoresis was carried out for 12 to 16 h on a
nondenaturing 0.5  MDE gel with and without glycerol at room
temperature and at 41C. The vacuum-dried gels were exposed to
x-ray films for 6 to 8 h, and bands for both single and double strands
were checked for aberrant migrations.
Sequence analysis Mutations detected with SSCP/heteroduplex
analysis in different exons of the BRAF and N-ras genes were
identified and confirmed by direct sequencing using Rhodamine
dye terminator cycle sequencing kit (Big Dye, Applied Biosystems,
Foster City, CA). Mutations were also confirmed by sequencing the
DNA extracted from aberrantly shifted bands that were excised
bands from the SSCP gels. Individual exons containing mutations
were amplified by PCR. The amplified products were purified using
Sephadex microspin columns (Amersham-Pharmacia, Piscataway,
NJ) and subjected to 26 cycles of sequencing reaction using
forward or reverse primers separately (Table II). The precipitated
sequencing reaction products were electrophoresed on a denatur-
ing polyacrylamide gel in an automated sequencer (ABI 377,
Applied Biosystems) and analyzed using Prism and Edit View 1.0.1
software. The sequencing data were analyzed using Align software
in DNA star package using the reference sequences of the BRAF
(accession No. NT_007914), N-ras (accession No. NT_019273),
and CDKN2A (accession No. AH005371) genes obtained from the
NCBI gene data bank (http://www.ncbi.nlm.nih.gov).
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